Health
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline
FRAMINGHAM, Mass. & SALISBURY, England, February 18, 2026--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the newly published International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary Angioedema recommends EKTERLY® (sebetralstat) as a first-line therapy for the acute treatment of hereditary angioedema (HAE) attacks in adolescents aged 12 years and older.1
About this update from Kalvista Pharmaceuticals, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":474,"url":"https://media.zenfs.com/en/business-wire.com/16f27fd0cfa5f6f41fdde13ed39fa248"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PLNmT2oXNXB.EFC_8CnSpg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/16f27fd0cfa5f6f41fdde13ed39fa248","width":480,"height":474}},"lazy":false},{"type":"text","content":"Guideline recommends ensuring on-demand treatment is available anytime, anywhere and prioritizes early intervention and rapid self-administration, reinforcing the unique value of EKTERLY","length":186,"tagName":"p","attribs":{}},{"type":"text","content":"FRAMINGHAM, Mass. & SALISBURY, England, February 18, 2026--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the newly published International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary Angioedema recommends EKTERLY® (sebetralstat) as a first-line therapy for the acute treatment of hereditary angioedema (HAE) attacks in adolescents aged 12 years and older.1","length":434,"tagName":"p"},{"type":"text","content":"Based on robust, high-quality evidence, including clinical trial data demonstrating consistent efficacy, rapid symptom relief and a favorable safety profile, the guideline committee issued a strong recommendation for the first-line use of sebetralstat in adolescents 12 and older with HAE. The recommendation comes just months after the launch of EKTERLY in the US and Germany and follows seven global regulatory approvals received in 2025. EKTERLY is the first and only oral on-demand treatment for people 12 and older with HAE.","length":529,"tagName":"p"},{"type":"text","content":""We are encouraged to see this international guideline reflect the progress the HAE community has made toward more patient-centered care, particularly for adolescents," said Paul Audhya, MD, MBA, Chief Medical Officer of KalVista. "The first-line recommendation for EKTERLY so soon after becoming commercially available underscores the strength of our clinical data and reinforces the importance of ensuring patients have immediate access to effective on-demand therapy. As the first and only oral on-demand treatment f...